Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | HCK | P08631 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072167 | 0.77 | F2 (0.33) | — | |
| SCHEMBL1083554 | 0.77 | F2 (0.33) | — | |
| SCHEMBL699047 | 0.72 | GAA (0.32) | MAPT | |
| SCHEMBL20647147 | 0.71 | TSHR (0.44) | MTORABL1PIK3CDEGFRHCK | |
| SCHEMBL34038 | 0.70 | IKBKB (0.31) | MTORABL1PIK3CDEGFRHCK | |
| SCHEMBL1800932 | 0.65 | — | — | |
| SCHEMBL693193 | 0.65 | SRC (0.36) | MTORABL1PIK3CDEGFRHCK | |
| SCHEMBL1800930 | 0.65 | — | — | |
| SCHEMBL5557928 | 0.65 | MAPT (0.31) | MAPTAGTR1 | |
| SCHEMBL20121338 | 0.64 | TOP2A (0.33) | MAPTAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274286-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | The Procter & Gamble Company (US) | 2011-01-19 | — | — | EP | claimed |
| US-7850742-B2 | Keratin dyeing compounds, keratin dyeing compositions containing said compounds, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2010-12-14 | — | — | US | claimed |
| WO-2009140451-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | NOXELL CORPORATION | 2009-11-19 | — | — | US | claimed |
| US-12133906-B2 | Delivery particle | THE PROCTER & GAMBLE COMPANY (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220409497-A1 | DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3733827-A1 | DELIVERY PARTICLES | The Procter & Gamble Company (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2563508-B1 | DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190142714-A1 | DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180360706-A1 | Delivery Particles | PROCTER & GAMBLE (US) | 2018-12-20 | — | — | US | disclosed |
| EP-2308564-B1 | Thickened hair colourant and bleaching compositions | NOXELL CORP (US) | 2018-12-19 | — | — | EP | disclosed |
| US-9993793-B2 | Delivery particles | THE PROCTER & GAMBLE COMPANY (US) | 2018-06-12 | — | — | US | disclosed |
| US-7850742-B2 | Keratin dyeing compounds, keratin dyeing compositions containing said compounds, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2010-12-14 | — | — | US | disclosed |
| WO-2010123866-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND A CHELANT AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123863-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010084480-A2 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010079466-A2 | DELIVERY PARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079468-A2 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009140451-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING SAID COMPOUNDS, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | NOXELL CORPORATION | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409497-A1 | DELIVERY PARTICLE | LIPA, CHMP4B, SLC46A1 | MTOR 4181/4885ABL1 4840/4885PIK3CD 2542/4885 |
| US-20180360706-A1 | Delivery Particles | LIPA, CHMP4B, ABCB4 | MTOR 4272/4885ABL1 4817/4885PIK3CD 2417/4885 |
| US-12133906-B2 | Delivery particle | LIPA, CHMP4B, SLC46A1 | MTOR 4181/4885ABL1 4840/4885PIK3CD 2542/4885 |
| US-20190142714-A1 | DELIVERY PARTICLE | LIPA, CHMP4B, SLC46A1 | MTOR 4181/4885ABL1 4840/4885PIK3CD 2542/4885 |
| US-20090282622-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Said Compounds, and Use Thereof | KRT18, TUBB3, PPOX | MTOR 1621/4885ABL1 4129/4885PIK3CD 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.